Aetna National Contract Adds 26M Members to CNSide Payer Footprint
CNSY is trading near its 52-week low of $1.16 (13% above the low) on elevated volume (51× avg).
Summary
CNSide Diagnostics, Cerenome's wholly owned subsidiary, signed a national in-network laboratory agreement with Aetna effective November 1, 2026, adding roughly 26 million medical members. It is the first national CNSide payer contract to cover both CSF tumor cell enumeration and molecular profiling for solid tumors and hematologic malignancies. Combined with prior deals, CNSide now has in-network agreements covering about 190 million lives, or roughly 85% of US private payers. This is the fourth payer win since August, following HCSC, Blue Cross Blue Shield of Michigan and Florida Blue, and it extends coverage from the core enumeration test to the higher-value molecular profile menu. The commercial ramp is still early — Q3 gross billings were $1.55 million on 222 tests — and the company reported a $9.0 million Q2 net loss with going-concern doubt and $8.6 million in cash, so reimbursement breadth is the main lever for revenue growth.
At the time of this announcement, CNSY was trading at $1.31 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $9.9M. The 52-week trading range was $1.16 to $18.89. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.